CD274 and breast carcinoma: As the clinical practice of PD-1/PD-L1 inhibitors in breast cancer is in full swing and the understanding is deepening, more and more clinical trials such as KEYNOTE-119 [10] and NEWBEAT [11] have confirmed the close connection between breast cancer and immunotherapy.